A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Peritoneal Metastases in Patients Undergoing Cytoreductive Surgery
Brief description of study
This study involves metastatic, stage 4 cancer, that has spread to your abdominal cavity and your cancer surgeon recommends surgery to remove cancer tumors from your abdomen. The purpose of this research study is to learn if the investigational study drug, pegsitacianine, helps in seeing the metastatic cancer disease left behind following the standard of care cancer surgery to remove the metastatic tumors. This study will also help to learn about the safety of the study drug and the ability to see the metastatic cancer tumors of each person in the study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Peritoneal Carcinomatosis
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, Age 18 or older Imaging and biopsy confirmed metastatic disease of peritoneal origin
Updated on
25 Aug 2023.
Study ID: 850056